The EPS miss and ATM offering create near-term bearish pressure. Monitor for PIVOT-006 topline data as a potential catalyst; a positive readout could offset dilution concerns. The BLA submission timeline (Q4 2026) is a key milestone. The stock may trade on pipeline updates rather than quarterly financials, but the capital raise signals significant cash needs before commercialization.
Price Chart
Executive Summary
CG Oncology reported Q2 2026 EPS of -$0.90, significantly wider than the consensus estimate of -$0.64 (a 40.6% miss), with revenue of $1.157M (vs consensus $363K, a 218.7% beat). The net loss widened to $79.1M from $41.4M a year ago, driven by a 74% increase in R&D spend and a 66% increase in G&A costs. The stock is likely to be pressured by the EPS miss and the concurrent $500M ATM equity offering, which signals aggressive funding needs and potential dilution, partially offset by the revenue beat and positive pipeline milestones (PIVOT-006 topline data expected soon, BLA submission in Q4 2026). The company has $1.0B in cash, sufficient through 2029, but the massive capital raise overshadows the near-term outlook.
Key Financial Metrics
Key Facts
- Q2 2026 EPS of -$0.90 missed consensus of -$0.64 by 40.6%
- Q2 2026 revenue of $1.157M beat consensus of $363K by 218.7%
- Net loss widened to $79.1M from $41.4M YoY, driven by higher R&D ($54.7M vs $31.3M) and G&A ($29.0M vs $17.4M) expenses
- Cash, cash equivalents and marketable securities at $1.0B, down from $1.1B in Q1 2026; sufficient through 2029
- Concurrent $500M ATM equity offering upsized to $1.05B total, representing potential ~7.8% dilution at current prices
- PIVOT-006 Phase 3 topline data for intermediate-risk NMIBC anticipated near-term; BLA submission for HR BCG-unresponsive NMIBC expected Q4 2026
- BOND-003 Cohort C results published in The Lancet Oncology in July 2026
- Delaware Superior Court upheld jury verdict in favor of CG Oncology in ANI litigation
Financial Impact
Net loss of $79.1M in Q2 2026, EPS miss of $0.26 vs consensus, and a $500M ATM offering creating dilution risk
Risk Factors
- Dilution from the $500M ATM offering could pressure stock price
- Widening net loss and increasing cash burn rate may concern investors
- Clinical trial risks: PIVOT-006 topline data could disappoint
- Regulatory risk: BLA submission and potential FDA approval for cretostimogene are uncertain
- Litigation overhang from ANI dispute, though recent court ruling was favorable
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3340256 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 8w ago | Press Release | $74.85 $74.33 | ▲ +0.69% | ▲ +1.29% | $67.38 (+9.98%) |
Aug 6, 2026 8w ago | 424B5 | $74.85 $74.33 | ▲ +0.69% | ▲ +1.29% | $67.38 (+9.98%) |
Jul 27, 2026 9w ago | Press Release | $72.62 $78.95 | ▲ +8.72% | ▲ +5.34% | $67.38 (−7.22%) |
Jul 17, 2026 11w ago | Insider Cluster | $71.85 $75.03 | ▲ +4.43% | ▼ −0.02% | $67.38 (−6.22%) |
Jul 16, 2026 11w ago | Court Ruling | $69.50 $74.71 | ▲ +7.50% | ▲ +3.88% | $67.38 (−3.05%) |
Jun 24, 2026 14w ago | 144 | $72.84 $71.12 | ▼ −2.36% | ▼ −2.89% | $67.38 (−7.50%) |
Jun 22, 2026 14w ago | 144 | $65.73 $70.19 | ▲ +6.79% | ▲ +5.63% | $67.38 (+2.51%) |
Jun 12, 2026 16w ago | Institutional Cluster | $59.56 $75.24 | ▲ +26.33% | ▲ +24.55% | $67.38 (+13.13%) |
May 26, 2026 18w ago | 8-K | $61.89 $70.25 | ▲ +13.50% | ▲ +15.45% | $67.38 (+8.87%) |
May 15, 2026 20w ago | Press Release | $66.93 $59.56 | ▼ −11.01% | ▼ −13.13% | $67.38 (+0.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access